These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


252 related items for PubMed ID: 27747762

  • 1. Apremilast: A Phosphodiesterase 4 Inhibitor for the Treatment of Psoriatic Arthritis.
    Mease PJ.
    Rheumatol Ther; 2014 Dec; 1(1):1-20. PubMed ID: 27747762
    [Abstract] [Full Text] [Related]

  • 2. A Phase III, Randomized, Controlled Trial of Apremilast in Patients with Psoriatic Arthritis: Results of the PALACE 2 Trial.
    Cutolo M, Myerson GE, Fleischmann RM, Lioté F, Díaz-González F, Van den Bosch F, Marzo-Ortega H, Feist E, Shah K, Hu C, Stevens RM, Poder A.
    J Rheumatol; 2016 Sep; 43(9):1724-34. PubMed ID: 27422893
    [Abstract] [Full Text] [Related]

  • 3. Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor.
    Kavanaugh A, Mease PJ, Gomez-Reino JJ, Adebajo AO, Wollenhaupt J, Gladman DD, Lespessailles E, Hall S, Hochfeld M, Hu C, Hough D, Stevens RM, Schett G.
    Ann Rheum Dis; 2014 Jun; 73(6):1020-6. PubMed ID: 24595547
    [Abstract] [Full Text] [Related]

  • 4. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3).
    Edwards CJ, Blanco FJ, Crowley J, Birbara CA, Jaworski J, Aelion J, Stevens RM, Vessey A, Zhan X, Bird P.
    Ann Rheum Dis; 2016 Jun; 75(6):1065-73. PubMed ID: 26792812
    [Abstract] [Full Text] [Related]

  • 5. Long-term experience with apremilast in patients with psoriatic arthritis: 5-year results from a PALACE 1-3 pooled analysis.
    Kavanaugh A, Gladman DD, Edwards CJ, Schett G, Guerette B, Delev N, Teng L, Paris M, Mease PJ.
    Arthritis Res Ther; 2019 May 10; 21(1):118. PubMed ID: 31077258
    [Abstract] [Full Text] [Related]

  • 6. Longterm (52-week) results of a phase III randomized, controlled trial of apremilast in patients with psoriatic arthritis.
    Kavanaugh A, Mease PJ, Gomez-Reino JJ, Adebajo AO, Wollenhaupt J, Gladman DD, Hochfeld M, Teng LL, Schett G, Lespessailles E, Hall S.
    J Rheumatol; 2015 Mar 10; 42(3):479-88. PubMed ID: 25593233
    [Abstract] [Full Text] [Related]

  • 7. Apremilast: A Review in Psoriasis and Psoriatic Arthritis.
    Keating GM.
    Drugs; 2017 Mar 10; 77(4):459-472. PubMed ID: 28213862
    [Abstract] [Full Text] [Related]

  • 8. The pharmacodynamic impact of apremilast, an oral phosphodiesterase 4 inhibitor, on circulating levels of inflammatory biomarkers in patients with psoriatic arthritis: substudy results from a phase III, randomized, placebo-controlled trial (PALACE 1).
    Schafer PH, Chen P, Fang L, Wang A, Chopra R.
    J Immunol Res; 2015 Mar 10; 2015():906349. PubMed ID: 25973439
    [Abstract] [Full Text] [Related]

  • 9. Early and sustained efficacy with apremilast monotherapy in biological-naïve patients with psoriatic arthritis: a phase IIIB, randomised controlled trial (ACTIVE).
    Nash P, Ohson K, Walsh J, Delev N, Nguyen D, Teng L, Gómez-Reino JJ, Aelion JA, ACTIVE investigators.
    Ann Rheum Dis; 2018 May 10; 77(5):690-698. PubMed ID: 29343507
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Network Meta-Analysis of Tofacitinib, Biologic Disease-Modifying Antirheumatic Drugs, and Apremilast for the Treatment of Psoriatic Arthritis.
    Gladman DD, Orbai AM, Gomez-Reino J, Chang-Douglass S, Leoncini E, Burton HE, Kanik KS, Romero AB, Cappelleri JC, Hsu MA.
    Curr Ther Res Clin Exp; 2020 May 10; 93():100601. PubMed ID: 32983284
    [Abstract] [Full Text] [Related]

  • 15. New developments in the management of psoriasis and psoriatic arthritis: a focus on apremilast.
    Palfreeman AC, McNamee KE, McCann FE.
    Drug Des Devel Ther; 2013 May 10; 7():201-10. PubMed ID: 23569359
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Apremilast for biologic-naïve, peripheral psoriatic arthritis, including patients with early disease: results from the APROACH observational prospective study.
    Sfikakis PP, Vassilopoulos D, Katsifis G, Vosvotekas G, Dimitroulas T, Sidiropoulos P, Vounotrypidis P, Bogdanos DP, Georgountzos AΙ, Bounas AG, Georgiou P, Gazi S, Kataxaki E, Liossis SN, Theodorou E, Papagoras C, Theotikos E, Vlachoyiannopoulos P, Voulgari PV, Kekki A, Antonakopoulos N, Boumpas DT.
    Rheumatol Int; 2023 May 10; 43(5):889-902. PubMed ID: 36856816
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 13.